<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1739">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04354428</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00009878</org_study_id>
    <secondary_id>INV-017062</secondary_id>
    <nct_id>NCT04354428</nct_id>
  </id_info>
  <brief_title>Treatment for COVID-19 in High-Risk Adult Outpatients</brief_title>
  <official_title>Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus&#xD;
      2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching&#xD;
      goal of this study is to assess the effectiveness of interventions on the incidence of lower&#xD;
      respiratory tract infection (LRTI) progression among high-risk adult outpatients with&#xD;
      SARS-CoV-2 infection to inform public health control strategies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, multi-center, placebo-equivalent (ascorbic acid + folic&#xD;
      acid)-controlled, blinded platform trial. Eligible participants will be enrolled and&#xD;
      randomized to Hydrocychloroquine (HCQ) + placebo (folic acid), HCQ + azithromycin,&#xD;
      lopinavir-ritonavir (LPV/r) or placebo (ascorbic acid + folic acid). Initially, this study&#xD;
      will enroll up to 495 eligible adults ( with high risk for Lower respiratory tract infection&#xD;
      (LRTI) progression at baseline who are PCR-confirmed SARS-CoV-2 infection (165 per arm). An&#xD;
      additional cohort of 135 eligible adults without risk factors for LRTI progression at&#xD;
      baseline who are PCR-confirmed SARS-CoV-2 infection will be enrolled for the co-primary&#xD;
      virologic outcome. During the 28 study days, participants will take the medication, complete&#xD;
      surveys, collect mid nasal swab for viral quantification, and assess symptoms for progression&#xD;
      to LRTI. Additional arms will be added should new potential agents be discovered or&#xD;
      combination treatments be proposed. In addition, arms may be dropped prior to completion if&#xD;
      deemed futile or if there is a safety signal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 16, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lower respiratory tract infection (LRTI) rates</measure>
    <time_frame>28 days from enrolment</time_frame>
    <description>Resting blood oxygen saturation (SpO2&lt;93%) level sustained for 2 readings 2 hours apart and presence of subjective dyspnea or cough</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of hospitalization or mortality</measure>
    <time_frame>Day 28 after enrolment</time_frame>
    <description>Cumulative incidence of hospitalization or mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in upper respiratory viral shedding</measure>
    <time_frame>Day 1 through Day 14 after enrolment</time_frame>
    <description>Time to clearance of nasal SARS-CoV-2, defined as 2 consecutive negative swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only]</measure>
    <time_frame>Day 1 through Day 14 after enrolment</time_frame>
    <description>COVID-19 symptoms are based on the following criteria:&#xD;
At least TWO of the following symptoms: Fever (≥ 38ºC), chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorder(s), OR&#xD;
At least ONE of the following symptoms: cough, shortness of breath or difficulty breathing, OR&#xD;
Severe respiratory illness with at least 1 of the following:&#xD;
Clinical or radiological evidence of pneumonia, OR&#xD;
Acute respiratory distress syndrome (ARDS), OR&#xD;
LRTI, defined by resting SpO2&lt;93% sustained for 2 readings 2 hours apart AND presence of subjective dyspnea or cough Death or COVID-19-related hospitalizations will count as a failure to resolve symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of participant-reported adverse events</measure>
    <time_frame>28 days from enrolment</time_frame>
    <description>Serious adverse events (including death and hospitalization) and adverse events resulting in treatment discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19-related hospitalization days</measure>
    <time_frame>28 days from enrolment</time_frame>
    <description>Duration of hospitalization among persons who become hospitalized with COVID-19 disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of disease severity</measure>
    <time_frame>Day 1 through Day 14 after enrolment</time_frame>
    <description>Peak score on WHO Ordinal Scale for Clinical Improvement&#xD;
Peak score on modified inFLUenza patient-reported outcome (Flu-PRO) instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral shedding rates</measure>
    <time_frame>Day 1 through Day 14 after enrolment</time_frame>
    <description>Proportion of days with SARS-CoV-2 detected from mid-nasal swabs by PCR&#xD;
Median quantity of SARS-CoV-2 detected from mid-nasal swabs by PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only]</measure>
    <time_frame>28 days from enrolment</time_frame>
    <description>PK-evaluable participants will have post-hoc individual concentration profiles and exposure estimates determined for exploratory exposure-response analyses against primary and secondary efficacy and safety endpoints</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Ascorbic acid and Folic acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ascorbic acid 500 mg orally twice on Day 1, followed by 250 mg orally twice daily for 9 days + folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days (Days 2 to 5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine and Folic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + placebo (folic acid 800 µg orally once on Day 1, followed by 400 µg orally once daily for an additional 4 days [Days 2 to 5])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine and Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCQ 400 mg orally twice on Day 1, followed by 200 mg orally twice daily for an additional 9 days (Days 2 to 10) + azithromycin 500 mg orally once on Day 1, followed by 250 mg orally once daily for an additional 4 days (Days 2 to 5).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lopinavir-ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LPV/r 800 mg-200 mg orally twice on Day 1, followed by 400 mg 100 mg orally twice daily for an additional 9 days (Days 2 to 10)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ascorbic acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ascorbic acid 1 gm orally twice on Day 1, followed by 500 mg orally twice daily for 9 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy</description>
    <arm_group_label>Ascorbic acid</arm_group_label>
    <arm_group_label>Ascorbic acid and Folic acid</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine Sulfate</intervention_name>
    <description>Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy</description>
    <arm_group_label>Hydroxychloroquine and Azithromycin</arm_group_label>
    <arm_group_label>Hydroxychloroquine and Folic Acid</arm_group_label>
    <other_name>Intervention A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy</description>
    <arm_group_label>Hydroxychloroquine and Azithromycin</arm_group_label>
    <other_name>Intervention B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>Eligible participants in a household will receive folic acid and an additional intervention drug</description>
    <arm_group_label>Ascorbic acid and Folic acid</arm_group_label>
    <arm_group_label>Hydroxychloroquine and Folic Acid</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]</intervention_name>
    <description>Eligible participants in a household randomized to this study arm will receive lopinavir-ritonavir therapy</description>
    <arm_group_label>Lopinavir-ritonavir</arm_group_label>
    <other_name>Intervention C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women 18 to 80 years of age, inclusive, at the time of signing the informed&#xD;
             consent&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  Laboratory confirmed SARS-CoV-2 infection, with test results within past 72 hours&#xD;
&#xD;
          -  COVID-19 symptoms, based on the following criteria: At least TWO of the following&#xD;
             symptoms: Fever (≥ 38ºC), chills, rigors, myalgia, headache, sore throat, new&#xD;
             olfactory and taste disorder(s), OR o At least ONE of the following symptoms: cough,&#xD;
             shortness of breath or difficulty breathing (Lopinavir-Ritonavir Platform)&#xD;
&#xD;
          -  Access to device and internet for Telehealth visits&#xD;
&#xD;
          -  At increased risk of developing severe COVID-19 disease (at least one of the&#xD;
             following)&#xD;
&#xD;
               1. Age ≥60 years&#xD;
&#xD;
               2. Presence of pulmonary disease, specifically moderate or severe persistent asthma,&#xD;
                  chronic obstructive pulmonary disease, pulmonary hypertension, emphysema&#xD;
&#xD;
               3. Diabetes mellitus (type 1 or type 2), requiring oral medication or insulin for&#xD;
                  treatment&#xD;
&#xD;
               4. Hypertension, requiring at least 1 oral medication for treatment&#xD;
&#xD;
               5. Immunocompromised status due to disease (e.g., those living with human&#xD;
                  immunodeficiency virus with a CD4 T-cell count of &lt;200/mm3)&#xD;
&#xD;
               6. Immunocompromised status due to medication (e.g., persons taking 20 mg or more of&#xD;
                  prednisone equivalents a day, anti-inflammatory monoclonal antibody therapies, or&#xD;
                  cancer therapies)&#xD;
&#xD;
               7. Body mass index ≥30 (self-reported)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to HCQ or other 4-aminoquinoline compounds&#xD;
&#xD;
          -  Known hypersensitivity to azithromycin or other azalide or macrolide antibiotics&#xD;
&#xD;
          -  Currently hospitalized&#xD;
&#xD;
          -  Signs of respiratory distress prior to randomization, including respiratory rate &gt;24&#xD;
&#xD;
          -  Current medications include HCQ&#xD;
&#xD;
          -  Concomitant use of other anti-malarial treatment or chemoprophylaxis&#xD;
&#xD;
          -  History of retinopathy of any etiology&#xD;
&#xD;
          -  Psoriasis&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Chronic kidney disease (Stage IV or receiving dialysis)&#xD;
&#xD;
          -  Known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes&#xD;
             &lt;1500) or thrombocytopenia (&lt;100 K)&#xD;
&#xD;
          -  Concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen&#xD;
&#xD;
          -  Known cirrhosis&#xD;
&#xD;
          -  Known personal or family history of long QT syndrome&#xD;
&#xD;
          -  History of coronary artery disease with a history of graft or stent&#xD;
&#xD;
          -  History of heart failure, Class 2 or greater using the New York Heart Association&#xD;
             functional class&#xD;
&#xD;
          -  Taking medications associated with prolonged QT and known risk of torsades de points.&#xD;
             These medications may include some antipsychotic and antidepressant medications.&#xD;
             (Lopinavir-Ritonavir Platform)&#xD;
&#xD;
          -  Taking medications associated with prolonged QT such as antipsychotic medications or&#xD;
             antidepressants (e.g., citalopram, venlafaxine, and bupropion) and unable to stop&#xD;
             during the trial&#xD;
&#xD;
          -  Taking warfarin (Coumadin or Jantoven)&#xD;
&#xD;
          -  Known history of glucose-6-phosphate-dehydrogenase deficiency&#xD;
&#xD;
          -  History of myasthenia gravis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Johnston, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruth M. Rothstein CORE Center - Cook County Health</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Coordinating Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UW Virology Research Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Christine Johnston</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Outpatient</keyword>
  <keyword>Treatment</keyword>
  <keyword>COVID-19</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data from the study will be made available in accordance with the funder's open access policy.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Within 3 months of publication of primary results.</ipd_time_frame>
    <ipd_access_criteria>De-identified data from the study will be made available in accordance with the funder's open access policy.</ipd_access_criteria>
    <ipd_url>https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Hydroxychloroquine and Azithromycin arms</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Lopinavir-Ritonavir arm</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Hydroxychloroquine and Azithromycin arms</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_004.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Lopinavir-Ritonavir arm</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_005.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

